{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:04:19Z","timestamp":1791594259307,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"DOI":"10.1007\/s11606-026-10515-2","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:00:36Z","timestamp":1779127236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes"],"prefix":"10.1007","author":[{"given":"Jane Y.","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisha","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Moynihan","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-812X","authenticated-orcid":false,"given":"David J.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"10515_CR1","unstructured":"United Nations Office on Drugs and Crime. UNODC World Drug Report 2023. Executive Summary. 2023. Available from www.unodc.org\/res\/WDR-2023\/WDR23_Exsum_fin_SP.pdf. Accessed 15 Oct 2025."},{"issue":"16","key":"10515_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/DDDT.S342409","volume":"22","author":"A Kotli\u0144ska-Lemieszek","year":"2022","unstructured":"Kotli\u0144ska-Lemieszek A, \u017bylicz Z. Less well-known consequences of the long-term use of opioid analgesics: a comprehensive literature review. Drug Des Devel Ther. 2022;22;16:251-264. https:\/\/doi.org\/10.2147\/DDDT.S342409.","journal-title":"Drug Des Devel Ther."},{"issue":"3","key":"10515_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40429-023-00493-4","volume":"10","author":"JI Byanyima","year":"2023","unstructured":"Byanyima JI, Li X, Vesslee SA, Kranzler HR, Shi Z, Wiers CE. Metabolic profiles associated with opioid use and opioid use disorder: a narrative review of the literature. Curr Addict Rep. 2023;10(3):581-593. https:\/\/doi.org\/10.1007\/s40429-023-00493-4.","journal-title":"Curr Addict Rep."},{"issue":"1","key":"10515_CR4","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1038\/s41598-020-62556-0","volume":"10","author":"I Elman","year":"2020","unstructured":"Elman I, Howard M, Borodovsky JT, et al. (2020) Metabolic and addiction indices in patients on opioid agonist medication-assisted treatment: a comparison of buprenorphine and methadone. Sci Rep 10(1):5617. https:\/\/doi.org\/10.1038\/s41598-020-62556-0","journal-title":"Sci Rep"},{"issue":"5","key":"10515_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.5055\/jom.2018.0526","volume":"15","author":"MM Sweeney","year":"2019","unstructured":"Sweeney MM, Antoine DG, Nanda L, et al. Increases in body mass index and cardiovascular risk factors during methadone maintenance treatment. J Opioid Manag. 2019;15(5):367-374.https:\/\/doi.org\/10.5055\/jom.2018.0526.","journal-title":"J Opioid Manag."},{"issue":"8","key":"10515_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/add.14607","volume":"114","author":"T Winhusen","year":"2019","unstructured":"Winhusen T, Theobald J, Kaelber DC, Lewis D. Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: electronic health record findings. Addiction. 2019;114(8):1462-1470. https:\/\/doi.org\/10.1111\/add.14607.","journal-title":"Addiction."},{"issue":"1","key":"10515_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13722-022-00316-3","volume":"17","author":"E Pasman","year":"2022","unstructured":"Pasman E, Kollin R, Broman M, et al. Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities. Addict Sci Clin Pract. 2022;17(1):35. https:\/\/doi.org\/10.1186\/s13722-022-00316-3.","journal-title":"Addict Sci Clin Pract."},{"issue":"2","key":"10515_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4093\/dmj.2012.36.2.157","volume":"36","author":"S Zahra","year":"2012","unstructured":"Zahra S, Hossein S, Ali KV. Relationship between opium abuse and severity of depression in type 2 diabetic patients. Diabetes Metab J. 2012;36(2):157-162. https:\/\/doi.org\/10.4093\/dmj.2012.36.2.157.","journal-title":"Diabetes Metab J."},{"issue":"1","key":"10515_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1056\/NEJMra1802148","volume":"380","author":"ASB Bohnert","year":"2019","unstructured":"Bohnert ASB, Ilgen MA. Understanding links among opioid use, overdose, and suicide. N Engl J Med. 2019;380(1):71-79. https:\/\/doi.org\/10.1056\/NEJMra1802148.","journal-title":"N Engl J Med."},{"issue":"3","key":"10515_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/01.pra.0000351884.83377.e2","volume":"15","author":"A Fareed","year":"2009","unstructured":"Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract. 2009;15(3):227-34. https:\/\/doi.org\/10.1097\/01.pra.0000351884.83377.e2.","journal-title":"J Psychiatr Pract."},{"issue":"1","key":"10515_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/08897077.2017.1363122","volume":"39","author":"G Vallecillo","year":"2018","unstructured":"Vallecillo G, Robles MJ, Torrens M, et al. Metabolic syndrome among individuals with heroin use disorders on methadone therapy: prevalence, characteristics, and related factors. Subst Abus. 2018;39(1):46-51. https:\/\/doi.org\/10.1080\/08897077.2017.1363122.","journal-title":"Subst Abus."},{"key":"10515_CR12","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 9.Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S181-S206. https:\/\/doi.org\/10.2337\/dc25-S009.","DOI":"10.2337\/dc25-S009"},{"issue":"7","key":"10515_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","volume":"82","author":"ACS Pierret","year":"2025","unstructured":"Pierret ACS, Mizuno Y, Saunders P, et al. Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis. JAMA Psychiatry. 2025;82(7):643-653. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0679.","journal-title":"JAMA Psychiatry."},{"issue":"3","key":"10515_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31(3):951-962. https:\/\/doi.org\/10.1038\/s41591-024-03412-w.","journal-title":"Nat Med."},{"issue":"4","key":"10515_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","volume":"82","author":"CS Hendershot","year":"2025","unstructured":"Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.4789.","journal-title":"JAMA Psychiatry."},{"key":"10515_CR16","doi-asserted-by":"publisher","first-page":"114565","DOI":"10.1016\/j.physbeh.2024.114565","volume":"281","author":"RJ Herman","year":"2024","unstructured":"Herman RJ, Schmidt HD. Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence. Physiol Behav. 2024;281:114565. https:\/\/doi.org\/10.1016\/j.physbeh.2024.114565.","journal-title":"Physiol Behav."},{"issue":"9","key":"10515_CR17","doi-asserted-by":"publisher","first-page":"e2435247","DOI":"10.1001\/jamanetworkopen.2024.35247","volume":"7","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Wang Q, et al. Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder. JAMA Netw Open. 2024;7(9):e2435247. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.35247.","journal-title":"JAMA Netw Open."},{"issue":"8","key":"10515_CR18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2174\/011570159X349579241231080602","volume":"23","author":"A Sharafshah","year":"2025","unstructured":"Sharafshah A, Lewandrowski KU, Gold MS, et al. In silico pharmacogenomic assessment of glucagon-like peptide-1 (GLP1) agonists and the genetic addiction risk score (GARS) related pathways: implications for suicide ideation and substance use disorder. Curr Neuropharmacol. 2025;23(8):974-995. https:\/\/doi.org\/10.2174\/011570159X349579241231080602.","journal-title":"Curr Neuropharmacol."},{"issue":"1","key":"10515_CR19","doi-asserted-by":"publisher","first-page":"24433","DOI":"10.1038\/s41598-024-75965-2","volume":"14","author":"E Kornelius","year":"2024","unstructured":"Kornelius E, Huang JY, Lo SC, Huang CN, Yang YS. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci Rep. 2024;14(1):24433. https:\/\/doi.org\/10.1038\/s41598-024-75965-2.","journal-title":"Sci Rep."},{"issue":"6","key":"10515_CR20","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/dom.15538","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii GA, Marinelli C, Mannucci E, Rotella F. Glucagon-like peptide-1 receptor agonists and mental health: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(6):2505-2508. https:\/\/doi.org\/10.1111\/dom.15538.","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"10515_CR21","doi-asserted-by":"publisher","first-page":"e2526321","DOI":"10.1001\/jamanetworkopen.2025.26321","volume":"8","author":"DJ Ramsey","year":"2025","unstructured":"Ramsey DJ, Makwana B, Dani SS, et al. Glucagon-like peptide-1 receptor agonists and the risk of sight-threatening ophthalmic complications in patients with type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526321. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.26321.","journal-title":"JAMA Netw Open."},{"issue":"4","key":"10515_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274. https:\/\/doi.org\/10.7326\/M16-2607.","journal-title":"Ann Intern Med."},{"key":"10515_CR23","doi-asserted-by":"publisher","first-page":"706908","DOI":"10.3389\/fphar.2021.706908","volume":"12","author":"F Yang","year":"2021","unstructured":"Yang F, Zeng F, Luo X, et al. GLP-1 receptor: a new target for sepsis. Front Pharmacol. 2021;12:706908. https:\/\/doi.org\/10.3389\/fphar.2021.706908.","journal-title":"Front Pharmacol."},{"key":"10515_CR24","unstructured":"International Diabetes Federation. Facts & figures. 2025. Available from https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/. Accessed 15 Oct 2026."},{"key":"10515_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12888-015-0567-x","volume":"15","author":"H Koponen","year":"2015","unstructured":"Koponen H, Kautiainen H, Lepp\u00e4nen E, M\u00e4ntyselk\u00e4 P, Vanhala M. Association between suicidal behaviour and impaired glucose metabolism in depressive disorders. BMC Psychiatry. 2015;15:163. https:\/\/doi.org\/10.1186\/s12888-015-0567-x.","journal-title":"BMC Psychiatry."},{"issue":"11","key":"10515_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","volume":"184","author":"P Ueda","year":"2024","unstructured":"Ueda P, S\u00f6derling J, Wintzell V, et al. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med. 2024;184(11):1301-1312. https:\/\/doi.org\/10.1001\/jamainternmed.2024.4369.","journal-title":"JAMA Intern Med."},{"issue":"4","key":"10515_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bph.15682","volume":"179","author":"A Kabahizi","year":"2022","unstructured":"Kabahizi A, Wallace B, Lieu L, et al. Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics. Br J Pharmacol. 2022;179(4):600-624. https:\/\/doi.org\/10.1111\/bph.15682.","journal-title":"Br J Pharmacol."},{"key":"10515_CR28","doi-asserted-by":"publisher","first-page":"175628642513320","DOI":"10.1177\/17562864251332035","volume":"18","author":"J Si","year":"2025","unstructured":"Si J, Yu K, Hao J, Wang J, Zhang L. The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders. Ther Adv Neurol Disord. 2025;18:17562864251332035. https:\/\/doi.org\/10.1177\/17562864251332035.","journal-title":"Ther Adv Neurol Disord."},{"issue":"8","key":"10515_CR29","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","volume":"29","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol Psychiatry. 2024;29(8):2587-2598. https:\/\/doi.org\/10.1038\/s41380-024-02498-5.","journal-title":"Mol Psychiatry."},{"key":"10515_CR30","doi-asserted-by":"publisher","unstructured":"Donnelly B, Balkon J, Lasher C, Lynch V, Bidanset JH, Bianco J (1983) Evaluation of the methadone-alcohol interaction. I. Alterations of plasma concentration kinetics. J Anal Toxicol 7(5):246\u20138. https:\/\/doi.org\/10.1093\/jat\/7.5.246.","DOI":"10.1093\/jat\/7.5.246"},{"key":"10515_CR31","doi-asserted-by":"publisher","first-page":"1007980","DOI":"10.3389\/fendo.2022.1007980","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang B, Wang R, et al. Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis. Front Endocrinol (Lausanne). 2022;13:1007980. https:\/\/doi.org\/10.3389\/fendo.2022.1007980.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10515_CR32","unstructured":"Singer JA, Hamilton S. Expand access to methadone treatment: remove barriers to primary care practitioners prescribing methadone. Policy Analysis No. 960. Cato Institute. 2023. Available from www.cato.org\/policy-analysis\/expand-access-methadone-treatment. Accessed 15 Oct 2026."},{"key":"10515_CR33","unstructured":"United Nations Office on Drugs and Crime. Treatment for Opioid Use Disorder: Population Estimates - United States. 2022. Available from www.cdc.gov\/mmwr\/volumes\/73\/wr\/mm7325a1.htm. Accessed 4 Nov 2025."},{"issue":"9","key":"10515_CR34","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979-993. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976.","journal-title":"JAMA Psychiatry."},{"issue":"1","key":"10515_CR35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/ije\/dyaa126","volume":"50","author":"M Nalini","year":"2021","unstructured":"Nalini M, Khoshnia M, Kamangar F, et al. Joint effect of diabetes and opiate use on all-cause and cause-specific mortality: the Golestan cohort study. Int J Epidemiol. 2021;50(1):314-324. https:\/\/doi.org\/10.1093\/ije\/dyaa126.","journal-title":"Int J Epidemiol."},{"issue":"3","key":"10515_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11916-016-0549-9","volume":"20","author":"S Sen","year":"2016","unstructured":"Sen S, Arulkumar S, Cornett EM, et al. New pain management options for the surgical patient on methadone and buprenorphine. Curr Pain Headache Rep. 2016;20(3):16. https:\/\/doi.org\/10.1007\/s11916-016-0549-9.","journal-title":"Curr Pain Headache Rep."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10515-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10515-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10515-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:00:39Z","timestamp":1779127239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10515-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":36,"alternative-id":["10515"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10515-2","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"All authors have completed and submitted the ICMJE disclosures form. The authors have made the following disclosures: D.J.R.: Consultant \u2013 Regeneron Pharmaceuticals Inc.; Consultant \u2013 Beaver-Visitec International, Inc. The other authors have no proprietary or commercial interest in any materials discussed in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure(s)"}},{"value":"This study was reviewed by the Lahey Hospital & Medical Center Institutional Review Board and determined to be not human subjects research. The analysis used aggregate, de-identified data from a federated research network database; therefore, informed consent was not required. The study adhered to the Declaration of Helsinki and is reported in accordance with the REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement and the Structured Template for Planning and Reporting on the Implementation of Real-World Evidence Studies (STaRT-RWE) guidelines.No animal subjects were used in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Subjects"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}}]}}